Across TCGA pan-cancer cohorts, ACTRT3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ACTRT3 data layer compared with 21 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher ACTRT3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ACTRT3 expression acts as an unfavorable survival marker.

LUSC, LGG, and SKCM are the cancer types where ACTRT3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	II,III,IV	0.269	0.749	<.001	32	view →
LGG	DFS	Median	All	0.192	0.738	.005	6	view →
SKCM	DFS	Median	All	0.231	0.730	.004	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ACTRT3 tumor-vs-normal RNA expression · all ACTRT3 data types